A Walk in the PARP: Remodeling the Landscape of Newly Diagnosed Advanced Ovarian Cancer

Explore recent improvements in the use of PARP inhibitors to treat ovarian cancer with this on-demand Webcast and downloadable slides.
person default
Alexandra Leary, MD, PhD
Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci
person default
Frederik Marmé, MD, PhD

Downloadable Slidesets

In this slideset, CCO’s expert faculty explores the role of biomarkers and HRD when treating patients with ovarian cancer using PARP inhibitors.

person default Alexandra Leary, MD, PhD Released: December 22, 2020

In this downloadable slideset, CCO’s expert faculty reviews pharmacologic properties of approved PARP inhibitors in newly diagnosed ovarian cancer.

person default Frederik Marmé, MD, PhD Released: December 18, 2020

In this downloadable slideset, CCO’s expert faculty reviews PARP inhibitor-associated adverse events, including identification and their management in newly diagnosed ovarian cancer.

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci Released: December 22, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue